Research Article

The Peptide Vaccine Combined with Prior Immunization of a Conventional Diphtheria-Tetanus Toxoid Vaccine Induced Amyloid β Binding Antibodies on Cynomolgus Monkeys and Guinea Pigs

Akira Yano, 1 Kaori Ito, 2 Yoshikatsu Miwa, 3 Yoshito Kanazawa, 4 Akiko Chiba, 5 Yutaka Iigo, 6 Yoshinori Kashimoto, 6 Akira Kanda, 7 Shinji Murata, 7 and Mitsuhiro Makino 2

1 Iwate Biotechnology Research Center, 22-174-4 Narita, Kitakami, Iwate 024-0003, Japan
2 Venture Science Laboratories, R&D Division, Daiichi-Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
3 Quality Assurance Division, Hayashibara Co., Ltd., 675-1 Fujisaki, Naka-ku, Okayama 702-8006, Japan
4 R&D Planning Department, R&D Division, Daiichi-Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
5 Development Oversight Function, R&D Division, Daiichi-Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
6 Biological Research Department, Drug Discovery and Biomedical Technology Unit, Daiichi-Sankyo R&D Novare Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan
7 Biological Research Laboratories, R&D Division, Daiichi-Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan

Correspondence should be addressed to Akira Yano; akiray@ibrc.or.jp

Received 2 May 2015; Accepted 21 July 2015

Academic Editor: Pedro A. Reche

Copyright © 2015 Akira Yano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The reduction of brain amyloid beta (Aβ) peptides by anti-Aβ antibodies is one of the possible therapies for Alzheimer’s disease. We previously reported that the Aβ peptide vaccine including the T-cell epitope of diphtheria-tetanus combined toxoid (DT) induced anti-Aβ antibodies, and the prior immunization with conventional DT vaccine enhanced the immunogenicity of the peptide. Cynomolgus monkeys were given the peptide vaccine subcutaneously in combination with the prior DT vaccination. Vaccination with a similar regimen was also performed on guinea pigs. The peptide vaccine induced anti-Aβ antibodies in cynomolgus monkeys and guinea pigs without chemical adjuvants, and excessive immune responses were not observed. Those antibodies could preferentially recognize Aβ40, and Aβ42 compared to Aβ fibrils. The levels of serum anti-Aβ antibodies and plasma Aβ peptides increased in both animals and decreased the brain Aβ40 level of guinea pigs. The peptide vaccine could induce a similar binding profile of anti-Aβ antibodies in cynomolgus monkeys and guinea pigs. The peptide vaccination could be expected to reduce the brain Aβ peptides and their toxic effects via clearance of Aβ peptides by generated antibodies.

1. Introduction

Alzheimer’s disease (AD) is a neurodegenerative disease pathologically characterized by the deposition of the amyloid beta (Aβ) fragments derived from amyloid precursor protein (APP) in senile plaques and the accumulation of neurofibrillary tangles composed of tau protein [1, 2]. Increasing evidence suggests that accumulation of Aβ plays a central role in the onset and progression of AD, and therapeutic interventions have been directed toward the reduction of Aβ production using inhibitors of the β- and γ-secretase enzymes or enhancement of Aβ clearance by immunotherapy [3-5].

Regarding Aβ immunotherapy, both active immunization against Aβ and passive immunization with monoclonal Aβ antibodies were reported to attenuate amyloid plaque formation in the brains of APP transgenic mice [6-8]. These treatments also diminished the amyloid-associated pathology...
[9–11] and improved learning deficits [12, 13]. In the clinical trials of the AN1792 vaccine, the aggregated Aβ1–42 peptide with a QS-21 adjuvant, the long-term follow-up study analysis indicated that Aβ1–42 immunization resulted in clearance of amyloid plaques in patients with AD; however, this clearance did not lead to the prevention of progressive neurodegeneration [14]. In recent clinical trials, passive immunization with the anti-Aβ antibody, bapineuzumab and solanezumab, and intravenous immunoglobulin treatment failed to show a significant clinical benefit in patients with mild to moderate AD [15]. Although the clinical results were disappointing, there is a consensus in the field that Aβ immunotherapy by earlier intervention, targeting patients with early AD or mild cognitive impairment or presymptomatic subjects, could be an effective therapeutic and prophylactic strategy. Anti-amyloid combination therapies were also expected as a practical approach for AD by the results that inhibition of γ-secretase or β-secretase with anti-Aβ antibodies was more effective than either alone in animal models [16, 17].

Based on the clinical results of the study of AN1792, which was halted due to the development of meningoencephalitis potentially related to a proinflammatory T-cell-mediated immune response [18–20], next-generation vaccine strategies for AD treatment will remain promising if the vaccine induces autoantibodies (anti-Aβ antibodies) without excessive inflammatory responses.

We have previously reported an Aβ peptide vaccine constructed of two parts, a T-cell epitope peptide on the N-terminal side and a B-cell epitope peptide connected by a dilsyne linker (KK) to the C-terminal side of the peptide [21]. In order to enhance the immunogenicity of the peptide, a cell-attachment motif (RGD) was added to the N-terminal side of the peptide [21], and a multiagretope-type T-cell epitope was used for induction of antibodies to a wide range of MHC-II type individuals [22]. Although the Aβ1–42 peptide, the antigen of AN1792, is estimated to contain many T-cell epitopes including cytotoxic epitopes, the N-terminal region of Aβ was thought to be an effective and safer target [23–25]. Our vaccine contained only the Aβ1–13 as a target B-cell epitope peptide, which is estimated to contain few cytotoxic T-cell epitopes by in silico analysis [22]. Because the Aβ1–13 was as weak as the B-cell epitope, the utilization of the additional T-cell epitope peptide, recognizable by preexisting memory T-cells in the host, was necessary for induction of the antibody to Aβ1–13 [26]. We used the multiagretope-type T-cell epitope peptide from diphtheria toxin (DiTox1382–401). The diphtheria toxin was used as a conventional vaccine antigen, such as diphtheria and tetanus (DT) vaccines designed to induce the toxin-neutralizing antibodies by Th2 type humoral immunities, and the major memory T-cells responding to DT epitopes were estimated to induce Th2 type immune responses. Our peptide vaccine, the RGD-DiTox1382–401–KK-Aβ1–13 peptide, could induce the anti-Aβ antibodies to C57BL/6 by boosting the T-cell reaction preimmunized by DT vaccination without chemical adjuvants [26]. This result provided motivation to investigate whether our peptide vaccine will also be effective to other species.

In this study, we investigated the immunogenicity of the peptide with vaccination to cynomolgus monkeys and guinea pigs and studied the effects of antibodies by monitoring the Aβ peptides.

2. Methods

2.1. Peptides. A RGD-DiTox1382–401–KK-Aβ1–13 Peptide (RGD-AYNFVESINVQVHNSYN-KK-DAEFRHDSGYEVH, the numbers following DiTox indicated the position of the amino acids on the precursor protein of diphtheria toxin including the 32-amino acids signal peptide), synthesized and verified by MALDI-TOF/MS as over the 95% purity, was obtained from Operon Biotechnologies K.K. (Tokyo, Japan). The single-letter universally accepted notation for amino acids is used throughout this text. Human Aβ peptide fragments used in this study were purchased from AnaSpec, Inc. (CA, USA).

2.2. Animals. The vaccination studies on male cynomolgus monkeys (3 to 4 years of age at the start of the study) were performed at Mitsubishi Chemical Medience Corporation (Shibaura, Tokyo, Japan). Male guinea pigs (Slc:Hartley) were purchased from Japan SLC, Inc. (Hamamatsu, Japan), and immunization began at 5 weeks of age. All experimental procedures were performed in accordance with the in-house guideline of the Institutional Animal Care and Use Committee of Daiichi Sankyo Co., Ltd.

2.3. Immunization. Cynomolgus monkeys were primed with 0.5 mL of absorbed diphtheria-tetanus combined toxoid (DT vaccine: The Kitasato Institute, Tokyo, Japan) three weeks before peptide immunization. The Aβ peptide vaccine was subcutaneously administrated with 0.5 or 2.5 mg/0.5 mL/head eight times every two weeks.

Guinea pigs were primed subcutaneously with 50 μL/head of DT vaccine before the peptide immunization. Three weeks after the DT vaccination, guinea pigs were immunized subcutaneously with 200 μg/200 μL/head of RGD-DiTox1382–401–KK-Aβ1–13 peptide solution or 200 μL of vehicle (distilled water) for the control group. Four identical booster doses were given at 3-week intervals.

2.4. Sample Collection. Peripheral blood was collected every 2 weeks from the cynomolgus monkeys; then plasma and serum were prepared and stored at −20°C for the following experiments.

Approximately 100 μL of blood was collected from the guinea pigs by tail bleeding one week after each peptide administration. Plasma samples were prepared by centrifugation and stored individually with a complete protease inhibitor cocktail (Roche Diagnostics K.K., Tokyo, Japan). One week after the last booster dose, cerebrospinal fluid (CSF) was obtained; then the animals were bled and plasma samples were prepared. CSF and plasma samples were prepared by centrifugation and then stored at −20°C. The brains were removed, frozen on dry ice, and stored at −80°C for an ELISA assay.

2.5. ELISA for Anti-Aβ Antibodies. Plates were coated with Aβ1–42 dissolved in distilled water and then washed with
washed (0.05% Tween 20 in phosphate buffered saline; PBS). Next, the plates were blocked with 1% Block Ace (Bio-Rad Laboratories, Inc., Hercules, CA, USA) in PBS at room temperature and then washed with wash buffer. Plasma samples were diluted 100- to 1000-fold. The autologous 2H8 mouse monoclonal anti-Aβ antibody (Thermo Fisher Scientific K.K., Yokohama, Japan) was used to generate a calibration curve for antibody titers. Each sample was applied to a well and incubated at 4°C overnight. After washing the plate, the wells were incubated with horseradish peroxidase-(HRP-) conjugated anti-mouse IgG and anti-guinea pig antibody (Sigma-Aldrich Japan Inc., Tokyo, Japan) at 4°C for 2 h. Next, they were incubated with 2,2'-azino-di-[3-ethylbenzothiazoline-6 sulfonic acid] diammonium salt (ABTS) substrate (Bio-Rad Laboratories, Inc.) at room temperature in the dark. After sufficient color development had occurred, 2 M phosphate buffer was added to stop the reaction. The absorbance of each well at 405 nm was measured with a spectrophotometer and antibody titers were then calculated.

ELISAs for antibody epitope-mapping were performed using the following Aβ peptides: RGD-DisTox382-401-KK-A β1–13, A β1–13, A β1–40, A β1–42, and A β1–42 fibrils (fA β1–42) as an immobilized antigen, and ELISAs were performed in the same way as described above. The preparation of fA β1–42 is described as follows: Lyophilized A β1–42 in PBS was incubated at 37°C for three days and then the resulting Aβ solution was centrifuged at 4°C for 10 min at 10,000 × g, then the precipitated fraction was suspended in distilled water and used in this study.

2.6. ELISA for Brain and Plasma. The brains of guinea pigs were thawed on ice and then homogenized in 5 volumes (v/w) of 42% formic acid solution including protease inhibitors using a homogenizer and a sonicator and were incubated overnight at 37°C. The homogenates were centrifuged at 37,000 rpm for 60 min at 4°C (OptimaTM L-100XP, rotor 50.4Ti, Beckman Coulter, Inc., Tokyo, Japan) and the supernatants were neutralized with 11 volumes (v/v) of 1 M Tris solution and then centrifuged at 10000 rpm for 10 min at 4°C (himac CT13R, Hitachi Koki Co., Ltd., Tokyo, Japan). The supernatants were collected as a brain Aβ fraction.

Levels of A β1–40 and A β1–42 in brain and plasma samples were measured using a Human/Rat β Amyloid (40) ELISA Kit Wako II (Wako Pure Chemical Industries, Ltd., Tokyo, Japan), Human/Rat β Amyloid (42) ELISA Kit Wako, High-Sensitive (Wako Pure Chemical Industries, Ltd.), and Human Amyloid β Oligomers (82El-specific) Assay Kit (IBL Co., Ltd., Gunma, Japan) and were used according to the manufacturer's instructions.

2.7. Detection of Cytokines from Peripheral Blood of Cynomol- gus Monkeys. Plasma of cynomolgus monkeys at days 22 to 36, 64 to 78, and 106 to 120 was pooled and used for the ELISA. IL-2, IL-4, IL-10, and TNFα were measured by a Monkey ELISA Kit (Invitrogen) according to the manufacturer's instruction.

2.8. A β1–42 Toxicity Assay. The soluble A β1–42 Peptide was added to the 7th day after passage of rat adrenal medulla derived pheochromocytoma, PCl2 (Dainippon Sumitomo Pharma Co., Ltd., Tokyo, Japan), cell line at 0 to 2 μM, and the viability of the cells was evaluated by AlamarBlue (Pierce, Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's instructions. The anti-A β1–42 mononclonal antibody (0.33 μM of 6E10, abcam, Cambridge, USA) was used as a control for the protection of PCl2 cells from cytotoxic A β1–42 peptide. The antibody (0.33 μM of mouse IgG, Sigma-Aldrich, St. Louis, MO, USA) was used as a negative control. The serum and antibodies were preincubated with A β1–42 peptides at 4°C for 2 h, then added to the cells, and cultured for 24 h.

2.9. Statistical Analysis. Data were expressed as mean ± standard error (SE). Data from the passive avoidance test and the brain, plasma, and CSF Aβ levels were analyzed by one-way analysis of variance (ANOVA). Data from the splenic T-cell proliferation assay were analyzed by the one-way layout and multiple comparison method of Dunnnett. SAS System Release 8.2 (SAS Institute Inc.) was used to perform all analyses and P values of less than 0.05 were considered to be statistically significant.

3. Results

3.1. Immunization of Aβ Peptide in Cynomolgus Monkeys. The time courses of plasma antibody concentration against the Aβ peptides by subcutaneous administration of the RGD-DisTox382-401-KK-A β1–13 peptide (0.5 and 2.5 mg/head) or vehicle (distilled water) in cynomolgus monkeys are shown in Figure 1(a). Compared to the vehicle group, the 2.5 mg peptide administrated group showed significantly higher antibody concentrations after the initial peptide administration (8 days after the first administration). To recognize the upper limit of the antibody concentration induced by the peptide, booster immunizations were continued over 100 days after the first immunization. The marked elevation following the third immunization was not observed and final serum antibody concentrations were reached about 8 times higher than that of the vehicle group. The plasma concentrations of Aβ40 were not significantly different between the groups, but the concentration of Aβ42 peptide in the 2.5 mg/head vaccination group was significantly higher than the vehicle group (Figure 1(b)). The result of epitope-mapping is indicated in Figure 1(c). The peptide induced antibodies recognized not only the Aβ vaccine peptide (KK-A β1–13) but also the full-length A β1–40 and A β1–42 Peptide. The antibodies were less reactive to Aβ fibrils (fA β1–42) than A β1–42 peptide. The antibody reactivities against the A β1–13 and A β1–10 peptide were relatively weaker than that against the A β1–13 peptide, suggesting that the C-terminal side of the A β1–13 epitope was the main epitope of the antibody generated by this peptide vaccination.

The cytokine responses to the peptide immunization were investigated by ELISA. Plasma of the cynomolgus monkeys at days 22 to 36, 64 to 78, and 106 to 120 was pooled and used for ELISA. IL-2, IL-4, IL-10, and TNFα were measured, but all cytokines remained under the detection limits (Table 1;
Figure 1: Induction of the anti-\(\beta\) antibodies and \(\beta\) peptides in the peripheral blood by immunization of the peptide vaccine to cynomolgus monkeys. The serum anti-\(\beta\) antibody levels of the cynomolgus monkeys treated with vehicle or RGD-DiTox\(_{20}\)-KK-\(\beta\)_1-13 (a). The plasma \(\beta\) and \(\beta\) peptide (b) level (nM) of cynomolgus monkeys. Diphtheria and tetanus toxoids (DT, 0.5 mL/head, s.c.) were administered to cynomolgus monkeys. Three weeks after the DT treatment, vehicle or the peptide (0.5 or 2.5 mg/head, s.c.) was administered at intervals of 2 weeks (arrows; total 9 times). Blood sampling was performed every week after the initial treatment. Results are represented as mean ± SE (n = 5). *P < 0.05 and **P < 0.01 as compared with the vehicle control group (the Dunnett test). Epitope-mapping of plasma anti-\(\beta\) antibodies immunized with vehicle or RGD-DiTox\(_{382-401}\)-KK-\(\beta\)_1-13 peptide (c). Epitope-mapping of antibodies was performed using each peptide-precoated ELISA with plasma collected at two weeks after the final treatment. Results are represented as mean ± SE (n = 5). KK-\(\beta\)_1-13: RGD-DiTox\(_{20}\)-KK-\(\beta\)_1-13 peptide.
3.2. Immunization of Aβ Peptide in Guinea Pigs. The Aβ peptide, RGD-DiTox$_{382-401}$-KK-Aβ$_{1-13}$ peptide (200 μg/head), or vehicle (distilled water) was subcutaneously administrated in guinea pigs. Compared to the vehicle group, the peptide administrated group showed 6 to 8 times higher antibody titers throughout the experiment (data not shown). The epitope-mapping performed with the serum from the final bleed indicated that the peptide vaccination induced antibodies in guinea pigs in the same patterns of epitopes as in cynomolgus monkeys except that the antibodies were reactive to FAβ as like as Aβ$_{1-42}$ peptide (Figure 2(a)).

The concentration of the plasma Aβ$_{1-40}$ peptide tended to increase due to the peptide immunization and showed a correlation with the level of anti-Aβ antibodies in the serum (Figure 2(b)). The concentration of the plasma Aβ$_{42}$ peptide was ten times lower than Aβ$_{40}$ peptide and their orders were unchanged by increasing anti-Aβ antibody concentration.

**Table 1:** Cytokines in the peripheral blood of cynomolgus monkeys.

|                  | Th1 type | Th2 type |
|------------------|----------|----------|
|                  | TNFα     | IL-2     | IL-4     | IL-10    |
| Control          | n.d.     | n.d.     | n.d.     | n.d.     |
| 0.5 mg/head-KK-Aβ peptide | n.d.     | n.d.     | n.d.     | n.d.     |
| 2.5 mg/head-KK-Aβ peptide | n.d.     | n.d.     | n.d.     | n.d.     |

Detection limits: TNFα 2 pg/mL, IL-2 2 pg/mL, IL-4 3 pg/mL, and IL-10 10 pg/mL.

TNFα < 2 pg/mL, IL-2 < 2 pg/mL, IL-4 < 3 pg/mL, and IL-10 < 10 pg/mL.
**Aβ1–42 Toxicity Assay with a Nerve Cell Culture.** To evaluate the protective effect of the peptide induced anti-Aβ antibodies, Aβ1–42 toxicity assay with a PC12 cell culture was performed. The anti-Aβ serum (25% final concentration) in cynomolgus monkeys collected one week after the final peptide immunization was investigated. Only the anti-Aβ antibody could protect PC12 cells from the toxic Aβ peptide (Figure 3(a)). The anti-Aβ serum of high-dose peptide-immunized monkeys protected PC12 cells from the damage of Aβ1–42 peptide (Figure 3(b)).

### 3.3. Aβ1–42 Toxicty Assay with a Nerve Cell Culture.

Figure 3: Effects of antiserum from cynomolgus monkeys vaccinated with RGD-DiTox382–401-KK-Aβ1–13 peptides or vehicle on Aβ-induced cytotoxicity of PC12 cells. The effects of the anti-Aβ monoclonal antibodies (positive control: black bar) and nonspecific immunoglobulin (gray bar) on the cytotoxicity of Aβ peptides (base control of cytotoxicity: white bar) are indicated (a). The effects of the serum of Aβ1–42 peptide-immunized monkey (0.5 mg/head low dose: black bar, and 2.5 mg/head high dose: gray bar) on the cytotoxic Aβ1–42 peptides (buffer control: white bar) are indicated.

The RGD-DiTox382–401-KK-Aβ1–13 peptide with preimmunized DT vaccine induced anti-Aβ antibodies in monkeys and guinea pigs without any chemical adjuvants. The vaccine peptide induced about 6 to 8 times higher anti-Aβ antibodies than vehicle-treated animals following third immunization. Those results clearly indicated the vaccine peptide was immunogenic to both kinds of animals. The multigrelopeptide T-cell epitope peptide on the N-terminal side of our peptide worked as T-cell epitope of DT vaccine to the animals with many types of MHC [22], and the results of guinea pigs and cynomolgus monkeys showed the T-cell epitopes of each animal were included in the peptide.

The T-cell epitope sequence was derived from conventional DT vaccine for induction of antibodies to Aβ peptide. Davtyan et al. [27] reported the same concept of AD peptide vaccine, Lu AF20513, that used memory Th cells generated by tetanus toxoid vaccine for induction of Aβ antibodies. Lu AF20513 was immunized with strong adjuvants, CFA/IFA, Quil-A or Alhydrogel, and more than several hundred times higher titers of antibodies were induced. It supported the availability of our peptide vaccine, if the arrangement of the epitopes and the amino acid sequence of T-cell epitope were different from our peptide. Our peptide would also induce more strong immune responses immunized with strong chemical adjuvants (supplemental experiments; see Supplementary Material available online at http://dx.doi.org/10.1155/2015/786501). In this study, we tried to avoid the induction of the strong immune responses for reduction of the risk by unexpected immune responses, namely, cytotoxic responses reported in the clinical trial of AN1792 [14]. The excessive entry of antibodies in the brain also might be a risk of encephalitis. Following the 9 administrations of the peptide, significant levels of cytokines were not induced in cynomolgus monkeys (Table 1).

**Figure 3:** Effects of antiserum from cynomolgus monkeys vaccinated with RGD-DiTox382–401-KK-Aβ1–13 peptides or vehicle on Aβ-induced cytotoxicity of PC12 cells. The effects of the anti-Aβ monoclonal antibodies (positive control: black bar) and nonspecific immunoglobulin (gray bar) on the cytotoxicity of Aβ peptides (base control of cytotoxicity: white bar) are indicated (a). The effects of the serum of Aβ1–42 peptide-immunized monkey (0.5 mg/head low dose: black bar, and 2.5 mg/head high dose: gray bar) on the cytotoxic Aβ1–42 peptides (buffer control: white bar) are indicated.
The result of the $A_{\beta1-42}$ toxicity assay using PC12 cells presented the effectiveness of the anti-$A_{\beta}$ serum induced by the weak immune responses by our peptide vaccination. In addition, our peptide vaccination induced antibodies working for clearance of $A_{\beta}$ peptides from the brain of the guinea pigs (Figure 2) [7]. The epitope-mapping of antibodies of both animals indicated the antibodies commonly recognize the C-terminal side of the $A_{\beta1-13}$, full-length $A_{\beta1-40}$, and $A_{\beta1-42}$ peptides (Figures 1b and 2a). $A_{\beta1-42}$ fibril was also recognized by antisera of guinea pigs but less reactive to antiserum of cynomolagus monkeys (Figures 2a and 1c). The antisera of our peptide would be more suitable for nerve cell protection from $A_{\beta1-42}$ peptides than dissolution of the $A_{\beta1-42}$ fibrils. This might be a major difference between AN1792 and our peptide. Lu AF20513 also used the $A_{\beta1-12}$ peptide as B-cell epitope, and the epitope of the induced antibodies was thought to be common between Lu AF20513 and our peptide. The antibodies induced by our peptide significantly increased the plasma $A_{\beta1-40}$ peptides and reduced the $A_{\beta1-40}$ peptides in the brains (Figures 1 and 2). It would be considered that the anti-$A_{\beta}$ antibodies transport the $A_{\beta}$ peptides from the brain to the blood stream [28, 29]. In contrast, plasma and brain $A_{\beta1-42}$ Peptide was always lower than $A_{\beta1-40}$ peptides and was not changed in the guinea pigs. It was expected that the basal level of $A_{\beta1-42}$ peptides in the wild type guinea pigs was three times lower than $A_{\beta1-40}$ peptide, and most of anti-$A_{\beta}$ antibodies would preferably react to $A_{\beta1-40}$ peptide compared to $A_{\beta1-42}$ peptide. Then it might be difficult to show the effects of the anti-$A_{\beta1-42}$ antibodies in Figure 2(d).

We also investigated the effect of the peptide vaccine by immunization of Tg2576 mice expressing the Swedish mutation of APP (APPK670N, K671L) (supplements). Unfortunately, the antibodies were not induced without chemical adjuvants and Freund’s incomplete adjuvant (FIA) was used three weeks after the DT vaccination. Tg2576 mice expressed excessive APPs in all tissues and strong adjuvants were necessary for induction of antibodies to $A_{\beta}$ peptides (Figure S1). The peptide vaccine could induce anti-$A_{\beta}$ antibodies to APP-Tg mice. The binding patterns of antibodies showed the same epitopes to guinea pigs and cynomolagus monkeys (Figure S1A). The results of the Tg2576 indicated that the vaccine induced antibodies increased $A_{\beta}$ peptides in plasma, which is consistent with the results in monkeys and guinea pigs, and CSF (Figures S1B, C, D, and E). The brain $A_{\beta}$ deposition and $A_{\beta}$ oligomer of APP-Tg mice reduced compared to vehicle-treated animals (Figures S1F, G, H, and I). Those results suggested that antibodies transported the $A_{\beta}$ peptides from the brain to the blood stream through the cerebrospinal fluid. We investigated memory changes in a passive avoidance test after the last booster vaccination. Compared to non-Tg mice, the learning impairment had already been initiated in Tg2576 mice at the initial immunization (data not shown). Six months after the initial immunization, the learning impairment in mice treated with $A_{\beta}$ peptide was significantly less than that in mice treated with vehicle, suggesting that $A_{\beta}$ peptide vaccination slowed the progression of learning impairment. Biochemical analysis indicated a significant reduction of the levels of insoluble $A_{\beta1-40}$, $A_{\beta1-42}$, and $A_{\beta}$ oligomers in the brain of KK-$A_{\beta}$ peptide vaccinated mice. A significant reduction of $A_{\beta1-42}$ immunostaining in the parietal cortex and hippocampus was also observed (data not shown) suggesting that the vaccination with the RGD-DiTox$^{382-401}$-KK-$A_{\beta1-13}$ peptide could have a potential to reduce and/or to inhibit the formation of senile plaques in the brains of Tg2576 mice. These results are similar to other findings of vaccinations [30, 31] and suggest that the vaccination with the RGD-DiTox$^{382-401}$-KK-$A_{\beta1-13}$ peptide might slow the progression of learning impairment mediated through the reduction of senile plaques, soluble $A_{\beta}$ oligomers, and/or inhibition of senile plaque formation in the brain. Those pharmaceutical effects, observed in Tg2576 mice, would be expected in wild type guinea pigs and cynomolagus monkeys.

5. Conclusions

RGD-DiTox$^{382-401}$-KK-$A_{\beta1-13}$ peptide vaccination in combination with a prior vaccination of the conventional diphtheria-tetanus combined toxoid vaccine induced anti-$A_{\beta10}$ and $A_{\beta40}$ antibodies in cynomolagus monkeys and guinea pigs. It promoted $A_{\beta}$ clearance in the brains of guinea pigs. The peptide vaccination did not show any excessive immune responses in any tested animals. We propose that this peptide would be a possible therapeutic or prophylactic candidate for AD.

Abbreviations

- $A_{\beta}$: Amyloid beta
- DT: Diphtheria-tetanus combined toxoid
- APP: Amyloid precursor protein
- AD: Alzheimer’s disease
- CSF: Cerebrospinal fluid
- PBS: Phosphate buffered saline
- HRP: Horseradish peroxidase
- BBB: Blood-brain barrier.

Conflict of Interests

The authors declared that they have no competing interests.

Authors’ Contribution

Akira Yano participated in the design of the study and in writing the paper. Kaori Ito, Yoshikatsu Miwa, Yoshito Kanazawa, and Mitsuhiro Makino participated in the design of the study and Kaori Ito, Mitsuhiro Makino, and Akiko Chiba performed the experiments. Yutaka Iigo and Yoshinori Kashimoto performed the data analysis. Akira Kanda and Shinji Murata supported the animal experiments. Akira Yano and Kaori Ito made equal contribution.

Acknowledgments

The authors would like to thank Chikako Nishimoto and Haruka Endo for their assistance in conducting the study. This work was supported by Daiichi-Sankyo Co., Ltd.
References

[1] J. Hardy and D. J. Selkoe, “The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002.

[2] A. Nikolaev, T. McLaughlin, D. D. M. O’Leary, and M. Tessier-Lavigne, “APP binds DR6 to trigger axon pruning and neuron death via distinct caspases,” Nature, vol. 457, no. 7232, pp. 981–989, 2009.

[3] M. S. Rafii and P. S. Aisen, “Recent developments in Alzheimer’s disease therapeutics,” BMC Medicine, vol. 7, article 7, 2009.

[4] D. M. Holtzman, J. C. Morris, and A. M. Goate, “Alzheimer’s disease: the challenge of the second century,” Science Translational Medicine, vol. 3, article 77sr1, 2011.

[5] M. Citron, “Alzheimer’s disease: strategies for disease modification,” Nature Reviews Drug Discovery, vol. 9, no. 5, pp. 387–398, 2010.

[6] D. Schenk, R. Barbour, W. Dunn et al., “Immunization with Amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse,” Nature, vol. 400, no. 6740, pp. 173–177, 1999.

[7] F. Bard, C. Cannon, R. Barbour et al., “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,” Nature Medicine, vol. 6, no. 8, pp. 916–919, 2000.

[8] D. M. Wilcock, A. Rojiani, A. Rosenthal et al., “Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage,” Journal of Neuroinflammation, vol. 1, article 24, 2014.

[9] J. A. Lombardo, E. A. Stern, M. E. McLellan et al., “Amyloid-β antibody treatment leads to rapid normalization of plaque-induced neuritic alterations,” The Journal of Neuroscience, vol. 23, no. 34, pp. 10879–10883, 2003.

[10] S. Oddo, L. Billings, J. P. Kesslak, D. H. Cribs, and F. M. LaFerla, “Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome,” Neuron, vol. 43, no. 3, pp. 321–332, 2004.

[11] R. P. Brendza, B. J. Backskai, J. R. Cirrito et al., “Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice,” The Journal of Clinical Investigation, vol. 115, no. 2, pp. 428–433, 2005.

[12] C. Janus, J. Pearson, J. McLaurin et al., “Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease,” Nature, vol. 408, no. 6815, pp. 979–982, 2000.

[13] D. Morgan, D. M. Diamond, P. E. Gottschall et al., “A β peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease,” Nature, vol. 408, no. 6815, pp. 982–985, 2000.

[14] C. Holmes, D. Boche, D. Wilkinson et al., “Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial,” The Lancet, vol. 372, no. 9634, pp. 216–223, 2008.

[15] M. Sarazin, G. Dorothée, L. C. de Souza, and P. Aucouturier, “Immunotherapy in Alzheimer’s disease: do we have all the pieces of the puzzle?” Biological Psychiatry, vol. 74, no. 5, pp. 329–332, 2013.

[16] E. Giacobini and G. Gold, “Alzheimer disease therapy—moving from amyloid-β to tau,” Nature Reviews Neurology, vol. 9, no. 12, pp. 677–686, 2013.

[17] H. Jacobsen, L. Ozmen, A. Caruso et al., “Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice,” The Journal of Neuroscience, vol. 34, no. 35, pp. 11621–11630, 2014.

[18] J.-M. Orgogozo, S. Gilman, J.-F. Dartigues et al., “Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization,” Neurology, vol. 61, no. 1, pp. 46–54, 2003.

[19] J. A. R. Nicoll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R. O. Weller, “Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report,” Nature Medicine, vol. 9, no. 4, pp. 448–452, 2003.

[20] I. Ferrer, M. Boada Rovira, M. L. Sánchez Guerra, M. J. Rey, and F. Costa-Jussà, “Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer’s disease,” Brain Pathology, vol. 14, no. 1, pp. 11–20, 2004.

[21] A. Yano, A. Onozuka, K. Matin, S. Imai, N. Hanada, and T. Nisizawa, “RGD motif enhances immunogenicity and adjuvancy of peptide antigens following intranasal immunization,” Vaccine, vol. 22, no. 2, pp. 237–243, 2003.

[22] A. Yano, A. Onozuka, Y. Asahi-Ozaki et al., “An ingenious design for peptide vaccines,” Vaccine, vol. 23, no. 17-18, pp. 2322–2326, 2005.

[23] D. S. Gelinas, K. DaSilva, D. Fenili, P. St. George-Hyslop, and J. McLaurin, “Immunotherapy for Alzheimer’s disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 2, pp. 14657–14662, 2004.

[24] F. Bard, R. Barbour, C. Cannon et al., “Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer’s disease-like neuropathology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 4, pp. 2023–2028, 2003.

[25] D. H. Cribs, A. Ghochikyan, V. Vasilyevko et al., “Adjuvant-dependent modulation of T1,1 and T1,2 responses to immunization with β-amloid,” International Immunology, vol. 15, no. 4, pp. 505–514, 2003.

[26] A. Yano, Y. Miwa, Y. Kanazawa et al., “A novel method for enhancement of peptide vaccination utilizing T-cell epitopes from conventional vaccines,” Vaccine, vol. 31, no. 11, pp. 1510–1515, 2013.

[27] H. Davtyan, A. Ghochikyan, I. Petrushina et al., “Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer’s disease: prelude to a clinical trial,” Journal of Neuroscience, vol. 33, no. 11, pp. 4923–4934, 2013.

[28] R. B. DeMattos, K. R. Bales, D. J. Cummins, J.-C. Dodart, S. M. Paul, and D. M. Holtzman, “Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 15, pp. 8850–8855, 2001.

[29] F. Lemiale, W.-P. Kong, L. M. Akyürek et al., “Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system,” Journal of Virology, vol. 77, no. 18, pp. 10078–10087, 2003.
[30] F. Goñi, F. Prelli, Y. Ji et al., “Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of alzheimer’s disease,” *PLoS ONE*, vol. 5, no. 10, Article ID e13391, 2010.

[31] S. Rasool, R. Albay III, H. Martinez-Coria et al., “Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice,” *Molecular Neurodegeneration*, vol. 7, no. 1, article 37, 2012.